The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Open accessAbstract
OBJECTIVE: This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. CONCLUSIONS: β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of β-cell failure; 2) identify and characterize genetic loci for T2D; 3) target β-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of β-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to β-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
A pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102 · cited 1×
“Individual miRNAs are highly represented in β-cells (31), impacting function and mass both positively and negatively.”
BackgroundInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Self-citationMasters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“β-cells, parallel to proinsulin, and can reach threshold levels that allow proapoptotic IAPP oligomers to form (44) that induce IL-1β release to recruit macrophages and enhance local islet inflammation (45).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 4×
“GLP-1based therapies magnify glucose-stimulated insulin secretion, as seen with significantly improved β-cell function in T2D following short-term infusions of GLP-1 (68, 69) and longer-”
BackgroundInfluentialGloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., & Herrera, P. L. (2010) · Nature · doi:10.1038/nature08894 · Cited by 1,136
Five stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126 · cited 1×
“This finding revisits an earlier one (35) suggesting β-cell dedifferentiation during disease development, although additional experimentation is needed to determine whether cells lose their defining β-cell characteristics temporarily; revert to an immature fetal or”
BackgroundSelf-citationSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · cited 1×
“evaluation of monogenic diabetes with therapeutic and prognostic implications (2-6).”
BackgroundWeng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780
Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.
Service, G. J., Thompson, G. B., Service, F. J., Andrews, J. C., Collazo-Clavell, M. L., & Lloyd, R. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043690 · Cited by 779
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
miR-375 maintains normal pancreatic α- and β-cell mass
Poy, M. N., Hausser, J., Trajkovski, M., Braun, M., Collins, S., Rorsman, P., Zavolan, M., & Stoffel, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810550106 · Cited by 740
Meier, J. J., Butler, A. E., Saisho, Y., Monchamp, T., Galasso, R., Bhushan, A., Rizza, R. A., & Butler, P. C. (2008) · Diabetes · doi:10.2337/db07-1369 · Cited by 683
Parental transmission of type 2 diabetes: the Framingham Offspring Study
Meigs, J. B., Cupples, L. A., & Wilson, P. W. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2201 · Cited by 666
Activating Mutations in the ABCC8 Gene in Neonatal Diabetes Mellitus
Babenko, A. P., Polak, M., Cavé, H., Busiah, K., Czernichow, P., Scharfmann, R., Bryan, J., Aguilar-Bryan, L., Vaxillaire, M., & Froguel, P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055068 · Cited by 655
Park, J. H., Stoffers, D. A., Nicholls, R. D., & Simmons, R. A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33655 · Cited by 640
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Circulating microRNAs as novel biomarkers for diabetes mellitus
Guay, C., & Regazzi, R. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.86 · Cited by 563 · cited 1×
“It has been suggested that altered miRNA expression may contribute toward b-cell failure in T2D and that these molecules may serve as biomarkers for the disease (30).”
BackgroundDayeh, T., Volkov, P., Salö, S., Hall, E., Nilsson, E., Olsson, A. H., Kirkpatrick, C. L., Wollheim, C. B., Eliasson, L., Rönn, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004160 · Cited by 523
Self-citationInactivation of specific β cell transcription factors in type 2 diabetes
Guo, S., Dai, C., Guo, M., Taylor, B., Harmon, J. S., Sander, M., Robertson, R. P., Powers, A. C., & Stein, R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65390 · Cited by 520
Self-citationEpigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion
Ling, C., Del Guerra, S., Lupi, R., Rönn, T., Granhall, C., Luthman, H., Masiello, P., Marchetti, P., Groop, L., & Del Prato, S. (2008) · Diabetologia · doi:10.1007/s00125-007-0916-5 · Cited by 495 · cited 2×
“studies of human pancreatic islets together with in vitro studies of clonal β-cells further suggest that hyperglycemia alters DNA methylation of PDX1 and INS (22-25).”
Self-citationLoss-of-function mutations in SLC30A8 protect against type 2 diabetes
Go-T2D Consortium, Flannick, J., T2D-GENES Consortium, Thorleifsson, G., Beer, N. L., Jacobs, S. B. R., Grarup, N., Burtt, N. P., Mahajan, A., Fuchsberger, C., et al. (2014) · Nature Genetics · doi:10.1038/ng.2915 · Cited by 492
Self-citationDiminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483 · cited 1×
“milieu, climbing glucose levels and deteriorating β-cell function are tightly correlated (49).”
BackgroundThe Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.8.2404 · Cited by 446
Arterburn, D. E., Bogart, A., Sherwood, N. E., Sidney, S., Coleman, K. J., Haneuse, S., O’Connor, P. J., Theis, M. K., Campos, G. M., McCulloch, D., et al. (2013) · Obesity Surgery · doi:10.1007/s11695-012-0802-1 · Cited by 426
Volkmar, M., Dedeurwaerder, S., Cunha, D. A., Ndlovu, M. N., Defrance, M., Deplus, R., Calonne, E., Volkmar, U., Igoillo‐Esteve, M., Naamane, N., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.503 · Cited by 420 · cited 2×
“studies of human pancreatic islets together with in vitro studies of clonal β-cells further suggest that hyperglycemia alters DNA methylation of PDX1 and INS (22-25).”
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Formation of a human β-cell population within pancreatic islets is set early in life
Gregg, B. E., Moore, P. C., Demozay, D., Hall, B. A., Li, M., Husain, A., Wright, A. J., Atkinson, M. A., & Rhodes, C. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1206 · Cited by 344 · cited 1×
“β-cell mass increases during the first decade of life due to proliferation during the first five years (53, 54), stabilizing during adolescence with considerable variation (3-5 fold) unrelated to age or BMI.”
BackgroundSelf-citationYang, B. T., Dayeh, T. A., Volkov, P. A., Kirkpatrick, C. L., Malmgren, S., Jing, X., Renström, E., Wollheim, C. B., Nitert, M. D., & Ling, C. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1004 · Cited by 301 · cited 2×
“Such studies of human pancreatic islets together with in vitro studies of clonal b-cells further suggest that hyperglycemia alters DNA methylation of PDX1 and INS (22–25).”
Self-citationFehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297
Islet β cell mass in diabetes and how it relates to function, birth, and death
Weir, G. C., & Bonner‐Weir, S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12031 · Cited by 296
Self-citationTODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2393 · Cited by 288
Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity
Cohen, R. V., Pinheiro, J. C., Schiavon, C. A., Salles, J. E., Wajchenberg, B. L., & Cummings, D. E. (2012) · Diabetes Care · doi:10.2337/dc11-2289 · Cited by 282
Marsk, R., Jonas, E., Rasmussen, F., & Näslund, E. (2010) · Diabetologia · doi:10.1007/s00125-010-1798-5 · Cited by 273 · cited 1×
“have not clearly dissected changes in insulin sensitivity from changes in β-cell function, augmented GLP-1 secretion amplifies RYGB’s antidiabetic effects on pancreatic islets (79), and post-RYGB hyperinsulinemic hypoglycemia may involve β-cell hypertrophy or neogenesis as well (80, 81).”
BackgroundPearson, E. R., Liddell, W. G., Shepherd, M., Corrall, R. J., & Hattersley, A. T. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00305.x · Cited by 259
Diabetes in old male offspring of rat dams fed a reduced protein diet
Petry, C. J., Dorling, M. W., Pawlak, D. B., Ozanne, S. E., & Hales, C. N. (2001) · Journal of Diabetes Research · doi:10.1155/edr.2001.139 · Cited by 254
Yang, B. T., Dayeh, T. A., Kirkpatrick, C. L., Taneera, J., Kumar, R., Groop, L., Wollheim, C. B., Nitert, M. D., & Ling, C. (2011) · Diabetologia · doi:10.1007/s00125-010-1967-6 · Cited by 251
Self-citationGastric bypass and banding equally improve insulin sensitivity and β cell function
Bradley, D., Conte, C., Mittendorfer, B., Eagon, J. C., Varela, J. E., Fabbrini, E., Gastaldelli, A., Chambers, K. T., Su, X., Okunade, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64895 · Cited by 244
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240
Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes
Rosengren, A. H., Braun, M., Mahdi, T., Andersson, S. A., Travers, M. E., Shigeto, M., Zhang, E., Almgren, P., Ladenvall, C., Axelsson, A. S., et al. (2012) · Diabetes · doi:10.2337/db11-1516 · Cited by 237
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
The genetic and epigenetic basis of type 2 diabetes and obesity
Drong, A. W., Lindgren, C. M., & McCarthy, M. I. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.149 · Cited by 212 · cited 1×
“, DNA methylation and histone modifications) can be active during fetal as well as postnatal and adult life and impact the level of expression of select genes associated with T2D (14).”
BackgroundRegression from pre-diabetes to normal glucose regulation in the diabetes prevention program
Perreault, L., Kahn, S. E., Christophi, C. A., Knowler, W. C., Hamman, R. F., & the Diabetes Prevention Program Research Group (2009) · Diabetes Care · doi:10.2337/dc09-0523 · Cited by 209
Dayeh, T. A., Olsson, A. H., Volkov, P., Almgren, P., Rönn, T., & Ling, C. (2013) · Diabetologia · doi:10.1007/s00125-012-2815-7 · Cited by 199
Self-citationStitzel, M. L., Sethupathy, P., Pearson, D. S., Chines, P. S., Song, L., Erdos, M. R., Welch, R., Parker, S. C. J., Boyle, A. P., Scott, L. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.012 · Cited by 193
Arslanian, S. A., Bacha, F., Saad, R., & Gungor, N. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.115 · Cited by 138
Genome-wide analysis of histone modifications in human pancreatic islets
Bhandare, R., Schug, J., Le Lay, J., Fox, A., Smirnova, O., Liu, C., Naji, A., & Kaestner, K. H. (2010) · Genome Research · doi:10.1101/gr.102038.109 · Cited by 136 · cited 1×
“Studies of pancreatic islets from non-diabetic donors (19, 20) and from patients with T2D (21) have identified epigenetic modifications in genes that potentially affect β-cell function.”
BackgroundAre we overestimating the loss of beta cells in type 2 diabetes?
Marselli, L., Suleiman, M., Masini, M., Campani, D., Bugliani, M., Syed, F., Martino, L., Focosi, D., Scatena, F., Olimpico, F., et al. (2014) · Diabetologia · doi:10.1007/s00125-013-3098-3 · Cited by 136
Reiner, T., Thurber, G., Gaglia, J., Vinegoni, C., Liew, C. W., Upadhyay, R., Kohler, R. H., Li, L., Kulkarni, R. N., Benoist, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109859108 · Cited by 120
Prevention of Diabetes With Pioglitazone in ACT NOW
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., et al. (2013) · Diabetes · doi:10.2337/db13-0265 · Cited by 109
In Vivo Insulin Sensitivity and Secretion in Obese Youth
Bacha, F., Gungor, N., Lee, S., & Arslanian, S. A. (2009) · Diabetes Care · doi:10.2337/dc08-1030 · Cited by 90
Targeting inflammation in the treatment of type 2 diabetes
Donath, M. Y. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12172 · Cited by 83 · cited 1×
“, IL-1b antagonism) can preserve some b-cell functional mass in T2D (47).”
BackgroundFoley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2167-8 · Cited by 83 · cited 1×
“term treatments with DPP-4 inhibitors (70) and GLP-1 receptor agonists (71, 72) However, while augmented insulin production as assessed with glucose- and arginine-stimulation continues during active treatment and is of clinical value, none of these agents has produced a meaningful, persistent change following therapy…”
Backgroundon behalf of the RISC Investigators, Ferrannini, E., Natali, A., Muscelli, E., Nilsson, P. M., Golay, A., Laakso, M., Beck-Nielsen, H., & Mari, A. (2011) · Diabetologia · doi:10.1007/s00125-011-2112-x · Cited by 80
Islets in type 2 diabetes: in honor of Dr. Robert C. Turner
Bonner-Weir, S., & O'Brien, T. D. (2008) · Diabetes · doi:10.2337/db07-1842 · Cited by 66 · cited 1×
“individuals (55-57), although current data suggest a 20-60% reduction (58).”
BackgroundRhee, N. A., Vilsbøll, T., & Knop, F. K. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01505.x · Cited by 47
Fluorescent exendin-4 derivatives for pancreatic β-cell analysis
Clardy, S. M., Keliher, E. J., Mohan, J. F., Sebas, M., Benoist, C., Mathis, D., & Weissleder, R. (2014) · Bioconjugate Chemistry · doi:10.1021/bc4005014 · Cited by 41
Metabolic surgery for type 2 diabetes
Cummings, D. E. (2012) · Nature Medicine · doi:10.1038/nm.2773 · Cited by 31
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Animal models of obesity and diabetes mellitus
Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.161 · Cited by 832
Vienberg, S., Geiger, J., Madsen, S., & Dalgaard, L. T. (2017) · Acta Physiologica · doi:10.1111/apha.12681 · Cited by 373
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells
Haythorne, E., Rohm, M., van de Bunt, M., Brereton, M. F., Tarasov, A. I., Blacker, T. S., Sachse, G., Silva dos Santos, M., Terron Exposito, R., Davis, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10189-x · Cited by 319
Metadata
- Authors
- Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-06-01
- Volume
- 99
- Issue
- 6
- Pages
- 1983-1992
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1996451419
- Cited by
- 222
- References
- 63
- FWCI
- 15.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.